OncoNano's pH-Sensitive Nanotechnology Platform Shows Promise for Antigen-Independent Cancer Drug Delivery
Key Insights
OncoNano Medicine (search) will present new preclinical data at AACR 2026 demonstrating the versatility of its ON-BOARD platform for tumor-targeted drug delivery through ultra pH (search)-sensitive micelle technology.
The company's lead candidate ONM-421 (search) showed broader anti-tumor activity compared to MMAE (search)-based antibody-drug conjugates, including efficacy in tumors with low target expression where ADCs were less active.
The platform overcomes key limitations of existing delivery approaches by targeting the acidic tumor microenvironment (search) rather than relying on tumor-associated antigens, potentially reducing off-tumor toxicities.
OncoNano Medicine (search) will showcase new preclinical data at the AACR Annual Meeting 2026 demonstrating the potential of its proprietary nanotechnology platform to overcome critical limitations in cancer (search) drug delivery. The clinical-stage biotechnology company's presentations will highlight the breadth of its ON-BOARD platform and its ability to enable effective, tumor-targeted delivery of therapeutic payloads through clinically validated ultra pH (search)-sensitive micelle technology designed to activate within the tumor microenvironment (search).
Platform Addresses Key Drug Delivery Challenges
"Our ON-BOARD platform is designed to overcome key limitations of existing delivery approaches, including reliance on tumor-associated antigens and off-tumor toxicities," said Kartik Krishnan, MD, PhD, Chief Executive Officer of OncoNano. "These data demonstrate the versatility of our platform across multiple payloads and reinforce its potential to deliver profound efficacy with an improved therapeutic index."
The ON-BOARD polymeric micelle platform leverages a universal tumor target—pH (search)—to precisely deliver anti-cancer (search) payloads to the tumor microenvironment (search). This approach represents a departure from traditional antibody-drug conjugates that rely on specific tumor-associated antigens for targeting.
Preclinical Data Demonstrates Platform Versatility
Two poster presentations will detail the platform's capabilities. The first presentation highlights the breadth and tunability of the ON-BOARD platform, demonstrating tumor-specific delivery of multiple cytotoxic compounds through targeting the acidic tumor microenvironment (search). Preclinical data show strong in vitro and in vivo anti-tumor activity across a range of payload-linker combinations, including superior tumor growth inhibition and robust responses compared to standard-of-care agents.
The findings illustrate the ability to modulate payload release through linker design, supporting a differentiated, antigen-independent approach to drug delivery. This tunability could enable optimization of therapeutic delivery for different cancer (search) types and treatment scenarios.
ONM-421 Shows Superior Performance in Preclinical Models
The second presentation features ONM-421 (search) as a lead example of ON-BOARD-enabled delivery. This pH (search)-responsive polymer-drug conjugate nanoparticle delivers MMAE (search) to solid tumors (search) and demonstrates antigen-independent antitumor efficacy in mouse models.
Preclinical findings demonstrate potent, antigen-independent anti-tumor efficacy across multiple xenograft models, including strong tumor growth inhibition and survival benefit. Notably, ONM-421 (search) showed broader activity compared to an MMAE (search)-based antibody-drug conjugate, including efficacy in tumors with low target expression where the ADC was less active.
In these models, ONM-421 (search) also demonstrated improved tolerability relative to a standard chemotherapy when given at an efficacious dose. The data highlight enhanced payload stability and protection during circulation, reinforcing the platform's ability to enable targeted tumor delivery while reducing off-target toxicity.
Technology Platform and Development Strategy
OncoNano's ON-BOARD platform is designed to improve the pharmacokinetic and pharmacodynamic properties of various payloads from small molecules to large biologics through encapsulation and localized tumor targeting. The company is utilizing this technology to generate a robust oncology pipeline to support novel therapeutic development for patients with high unmet medical needs.
The presentations will take place on April 20, 2026, from 2:00-5:00 PM PT in Poster Section 14 at the AACR Annual Meeting 2026, with specific details provided for each poster location and number.